Mohamed Hassan

Dr. Mohamed Hassan

University Medical Center Freiburg, Freiburg, Germany
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MRMichael Ried
Michael Ried
JKJulia Kovács
Julia Kovács
TMTill Markowiak
Till Markowiak
KMKarolina Müller
Karolina Müller
GHGunnar Huppertz
Gunnar Huppertz
HHHans-Stefan Hofmann
Hans-Stefan Hofmann
In the context of quality assurance, the objectives were to describe the surgical treatment and postoperative morbidity (particularly renal insufficiency). A retrospective, multicentre study of patients who underwent cytoreductive surgery (CRS) with cisplatin-based HITOC was performed. The study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation (GZ: RI 2905/3-1)). Patients (n = 350) with malignant pleural mesothelioma (n = 261; 75%) and thymic tumours with pleural spread (n = 58; 17%) or pleural metastases (n = 31; 9%) were analyzed. CRS was accomplished by pleurectomy/decortication (P/D: n = 77; 22%), extended P/D (eP/D: n = 263; 75%) or extrapleural pneumonectomy (EPP: n = 10; 3%). Patients received cisplatin alone (n = 212; 61%) or cisplatin plus doxorubicin (n = 138; 39%). Low-dose cisplatin (≤125 mg/m2 BSA) was given in 67% of patients (n = 234), and high-dose cisplatin (>125 mg/m2 BSA) was given in 33% of patients (n = 116). Postoperative renal insufficiency appeared in 12% of the patients (n = 41), and 1.4% (n = 5) required temporary dialysis. Surgical revision was necessary in 51 patients (15%). In-hospital mortality was 3.7% (n = 13). Patients receiving high-dose cisplatin were 2.7 times more likely to suffer from renal insufficiency than patients receiving low-dose cisplatin (p = 0.006). The risk for postoperative renal failure is dependent on the intrathoracic cisplatin dosage but was within an acceptable range.

14 December 2020 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
JSJoseph Seitlinger
Joseph Seitlinger
CWChristophe Wollbrett
Christophe Wollbrett
AMAntonio Mazzella
Antonio Mazzella
SSSeverin Schmid
Severin Schmid
FGFrancesco Guerrera
Francesco Guerrera
Stéphane RenaudStéphane Renaud
Stéphane Renaud

1 June 2021 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
MHMohamed Hassan
Mohamed Hassan
TGThomas Graeter
Thomas Graeter
IDIrene Dietrich
Irene Dietrich
LKLars Johann Kemna
Lars Johann Kemna
BPBernward Passlick
Bernward Passlick
SSSeverin Schmid
Severin Schmid
Objective: The surgical resection of pulmonary metastases is associated with a survival benefit in selected patients. The use of laser devices for pulmonary metastasectomy (PM) is believed to facilitate the complete resection of metastases while preserving a maximum of healthy parenchyma. This is a prospective study to evaluate surgical outcome including the changes of lung function after laser–assisted surgery (LAS).Methods: A total of 77 operations in 61 patients in which PM was carried out in a curative intent were analyzed. A 1.320 nm diode-pumped Nd: YAG-Laser was used for resection of the metastases. Surgical and clinical data were collected using a standardized form and postoperative lung function changes 3 and 6 months after surgery were assessed using whole body plethysmography and diffusion capacity for carbon monoxide (DLCO). Size and distance of metastases to the pleural surface were measured radiologically.Results: A median of two metastases were resected per operation (range 1–13). The median duration of postoperative air leak was 1 day (range 0–11). LAS associated postoperative minor and major complications were observed in 4 (5%) cases and 1 (1%) case, respectively; there were no mortalities. The analysis of perioperative lung function showed that mean VC 3 months after surgery was reduced by 11 %, FEV1 by 11% and median DLCO by 11% (all p < 0.0001). There was almost no recovery of lung function between 3 and 6 months in the whole cohort. Patients with two or less metastases showed a recovery of lung function after 3 months regarding DLCO (p = 0.003). Decline of DLCO in the whole cohort correlated with the number of resected metastases at 3 months (r = 0.45, p = 0.006) and at 6 months (r = 0.42, p = 0.02) as well as depth of metastases in the parenchyma at 6 months (r = 0.48, p = 0.001).Conclusions: LAS is a safe and effective method for PM even for higher numbers of metastases, with short duration of postoperative air leak and little morbidity. Number and depth, but not size of metastases affect lung function changes after resection.

26 June 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MHMohamed Hassan
Mohamed Hassan
EBEhle Benjamin
Ehle Benjamin
BPBernward Passlick
Bernward Passlick
KGKonstantinos Grapatsas
Konstantinos Grapatsas
Background: Pulmonary metastasectomy (PM) is an established treatment option for selected patients with stage IV solid tumors. The aim of this study was to investigate the feasibility of and survival rate in PM for elderly patients. Methods: We retrospectively analyzed all of the patients who underwent PM with curative intention at our institution. The patients were categorized into two groups: the elderly group (≥70 years old) and the non-elderly group (<70 years old). Results: The elderly group consisted of 222 patients versus 538 patients in the non-elderly group. The median number of resected metastases was 2 ± 3 in the elderly group and 4 ± 5 in the non-elderly group (p < 0.01). No difference in the rate of postoperative complications was observed between the two groups (p = 0.3). The median length of hospital stay in each group was comparable (10 ± 5 vs. 10 ± 4.3 days, p = 0.3). The 5-year survival rate was 67% in the elderly group and 78% in the non-elderly group (p = 0.117). In the univariate analysis, COPD was associated with poor survival in the elderly group (p = 0.002). Conclusion: The resection of pulmonary metastases in elderly patients is safe, is not associated with increased risks of postoperative complication, and the survival benefit is not reduced in selected patients.

20 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LKLaura V. Klotz
Laura V. Klotz
JZJulia Zimmermann
Julia Zimmermann
KMKarolina Müller
Karolina Müller
JKJulia Kovács
Julia Kovács
MHMohamed Hassan
Mohamed Hassan
MRMichael Ried
Michael Ried
Cytoreductive surgery (CRS) combined with hyperthermic intrathoracic chemoperfusion (HITOC) is a promising treatment strategy for pleural mesothelioma (PM). The aim of this study was to evaluate the impacts of this multimodal approach in combination with systemic treatment on disease-free survival (DFS) and overall survival (OS). In this retrospective multicenter study, clinical data from patients after CRS and HITOC for PM at four high-volume thoracic surgery departments in Germany were analyzed. A total of 260 patients with MPM (220 epithelioid, 40 non-epithelioid) underwent CRS and HITOC as part of a multimodal treatment approach. HITOC was administered with cisplatin alone (58.5%) or cisplatin and doxorubicin (41.5%). In addition, 52.1% of patients received neoadjuvant and/or adjuvant chemotherapy. The median follow-up was 48 months (IQR = 38 to 58 months). In-hospital mortality was 3.5%. Both the resection status (macroscopic complete vs. incomplete resection) and histologic subtype (epithelioid vs. non-epithelioid) had significant impacts on DFS and OS. In addition, adjuvant chemotherapy (neoadjuvant/adjuvant) significantly increased DFS (p = 0.003). CRS and HITOC within a multimodal treatment approach had positive impacts on the survival of patients with epithelioid PM after macroscopic complete resection. The addition of chemotherapy significantly prolonged the time to tumor recurrence or progression.

6 December 2021
Verified
Conference Paper
Closed access
CNChristopher Nixon
Christopher Nixon
MSMohamed Sedky
Mohamed Sedky
MHMohamed Hassan
Mohamed Hassan
Intrusion Detection Systems (IDS) monitor com-puter networks for attack. Network data streams are potentially infinite and require real-time processing in order to provide timely detection of changing attacks. To address the nature of the network data stream it is important to consider the use of online data stream learning methods for IDS. Online data stream learning is an extension of Machine Learning (ML) where special consideration is given to finding anomalies in the data stream via supervised and unsupervised methods, adapting to concept drift, processing real-time events, and management of labelling cost by using Active Learning (AL). This paper asks the question of which online data stream and AL methods for IDS have been recently reviewed? A Systematic Literature Review (SLR) was performed and found that there is currently no reviews available that focus primarily on IDS data stream learning. Reviews were organised into categories and key considerations presented.